RENOVE Trial Overview 📑
Mar 05, 2025•2 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
The RENOVE trial compared reduced-dose versus full-dose DOACs for extended venous thromboembolism VTE treatment in high-risk patients.
While the reduced dose cut major bleeding risk by 39% 🚨, it did not meet non-inferiority criteria for preventing VTE recurrence 🔄.
For the best experience, listen in Metacast app for iOS or Android